Imugene Limited (AU:IMU) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Imugene Limited has secured confirmation of an $11 million R&D tax refund from the Australian Taxation Office, expected in January 2025. This refund will bolster the company’s efforts in advancing its cutting-edge immuno-oncology pipeline, aimed at transforming cancer treatment. Imugene’s innovative therapies are poised to make significant impacts in the global cancer treatment market.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.
